NeuroPace (NPCE) Competitors $11.53 +0.39 (+3.50%) (As of 12/20/2024 05:16 PM ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends NPCE vs. ESTA, BLFS, PLSE, AORT, EMBC, CBLL, LQDA, EYE, BVS, and FNAShould you be buying NeuroPace stock or one of its competitors? The main competitors of NeuroPace include Establishment Labs (ESTA), BioLife Solutions (BLFS), Pulse Biosciences (PLSE), Artivion (AORT), Embecta (EMBC), CeriBell (CBLL), Liquidia (LQDA), National Vision (EYE), Bioventus (BVS), and Paragon 28 (FNA). These companies are all part of the "medical equipment" industry. NeuroPace vs. Establishment Labs BioLife Solutions Pulse Biosciences Artivion Embecta CeriBell Liquidia National Vision Bioventus Paragon 28 NeuroPace (NASDAQ:NPCE) and Establishment Labs (NASDAQ:ESTA) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their community ranking, valuation, profitability, earnings, risk, analyst recommendations, institutional ownership, media sentiment and dividends. Does the MarketBeat Community favor NPCE or ESTA? Establishment Labs received 89 more outperform votes than NeuroPace when rated by MarketBeat users. Likewise, 61.90% of users gave Establishment Labs an outperform vote while only 58.33% of users gave NeuroPace an outperform vote. CompanyUnderperformOutperformNeuroPaceOutperform Votes2858.33% Underperform Votes2041.67% Establishment LabsOutperform Votes11761.90% Underperform Votes7238.10% Which has stronger earnings & valuation, NPCE or ESTA? NeuroPace has higher earnings, but lower revenue than Establishment Labs. Establishment Labs is trading at a lower price-to-earnings ratio than NeuroPace, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioNeuroPace$76.45M4.50-$32.96M-$1.00-11.53Establishment Labs$153.07M7.32-$78.50M-$2.58-15.51 Is NPCE or ESTA more profitable? NeuroPace has a net margin of -36.74% compared to Establishment Labs' net margin of -46.13%. Establishment Labs' return on equity of -184.55% beat NeuroPace's return on equity.Company Net Margins Return on Equity Return on Assets NeuroPace-36.74% -205.41% -28.29% Establishment Labs -46.13%-184.55%-24.81% Do insiders & institutionals have more ownership in NPCE or ESTA? 78.8% of NeuroPace shares are held by institutional investors. Comparatively, 72.9% of Establishment Labs shares are held by institutional investors. 22.2% of NeuroPace shares are held by insiders. Comparatively, 11.4% of Establishment Labs shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth. Which has more risk & volatility, NPCE or ESTA? NeuroPace has a beta of 2.05, suggesting that its stock price is 105% more volatile than the S&P 500. Comparatively, Establishment Labs has a beta of 1.16, suggesting that its stock price is 16% more volatile than the S&P 500. Do analysts prefer NPCE or ESTA? NeuroPace currently has a consensus price target of $14.50, suggesting a potential upside of 25.76%. Establishment Labs has a consensus price target of $60.60, suggesting a potential upside of 51.46%. Given Establishment Labs' stronger consensus rating and higher probable upside, analysts plainly believe Establishment Labs is more favorable than NeuroPace.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score NeuroPace 0 Sell rating(s) 1 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 2.86Establishment Labs 0 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 3.00 Does the media refer more to NPCE or ESTA? In the previous week, NeuroPace had 6 more articles in the media than Establishment Labs. MarketBeat recorded 8 mentions for NeuroPace and 2 mentions for Establishment Labs. Establishment Labs' average media sentiment score of 0.95 beat NeuroPace's score of 0.81 indicating that Establishment Labs is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment NeuroPace 3 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Establishment Labs 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive SummaryEstablishment Labs beats NeuroPace on 10 of the 19 factors compared between the two stocks. Ad Behind the MarketsWe recommended Palantir in 2021, now we’re recommending this...My research indicates there is only one investment that can meet AI's unprecedented demand for energy.Click to get the name and ticker symbol Get NeuroPace News Delivered to You Automatically Sign up to receive the latest news and ratings for NPCE and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart NPCE vs. The Competition Export to ExcelMetricNeuroPaceSurgical & medical instruments IndustryMedical SectorNASDAQ ExchangeMarket Cap$344.15M$4.34B$5.12B$9.07BDividend YieldN/A41.46%4.91%4.22%P/E Ratio-11.5325.3791.3417.19Price / Sales4.5045.961,117.70116.80Price / CashN/A43.4542.6437.86Price / Book14.597.364.794.78Net Income-$32.96M$13.64M$120.07M$225.60M7 Day Performance4.53%-2.80%-1.90%-1.23%1 Month Performance28.11%0.56%11.45%3.37%1 Year Performance30.43%41.87%30.63%16.58% NeuroPace Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)NPCENeuroPace3.7644 of 5 stars$11.53+3.5%$14.50+25.8%+24.4%$344.15M$76.45M-11.53170Analyst ForecastPositive NewsESTAEstablishment Labs2.5211 of 5 stars$46.32+0.7%$60.60+30.8%+73.3%$1.30B$153.07M-17.83960Positive NewsBLFSBioLife Solutions1.2666 of 5 stars$27.19+1.8%$28.29+4.0%+79.4%$1.26B$146.96M-25.19409Analyst ForecastInsider TradeNews CoveragePLSEPulse Biosciences1.8256 of 5 stars$20.50+16.1%N/A+56.3%$1.26B$700,000.000.00140Insider TradeNews CoverageAORTArtivion2.2159 of 5 stars$29.10+0.6%$31.80+9.3%+59.5%$1.22B$384.90M-1,446.501,500EMBCEmbecta3.7712 of 5 stars$19.86+1.8%$23.00+15.8%+13.5%$1.15B$1.12B14.712,200Short Interest ↓CBLLCeriBellN/A$29.04-0.6%$32.60+12.3%N/A$1.04B$60.04M0.00N/ALQDALiquidia3.4225 of 5 stars$11.07+1.4%$24.00+116.8%+3.7%$936.93M$15.61M-6.7050Analyst ForecastNews CoveragePositive NewsEYENational Vision3.0673 of 5 stars$11.71+2.6%$14.00+19.6%-41.2%$922.16M$2.13B-57.0513,998Analyst RevisionNews CoveragePositive NewsBVSBioventus3.6174 of 5 stars$11.24+1.9%$16.00+42.3%+104.8%$912.18M$555.06M-18.081,200Analyst UpgradePositive NewsFNAParagon 283.0405 of 5 stars$10.73+3.0%$15.60+45.4%-17.7%$898.32M$245.00M-14.08343,000 Related Companies and Tools Related Companies Establishment Labs Alternatives BioLife Solutions Alternatives Pulse Biosciences Alternatives Artivion Alternatives Embecta Alternatives CeriBell Alternatives Liquidia Alternatives National Vision Alternatives Bioventus Alternatives Paragon 28 Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:NPCE) was last updated on 12/21/2024 by MarketBeat.com Staff From Our PartnersAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredVideo: Blindfolded Man Gets Into a Cybertruck… What Happens Next Will Shock You“Hi, I’m Jeff Brown… Even though I can’t see a thing… I’m about to get in this Cybertruck and drive up t...Brownstone Research | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode before 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding NeuroPace, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share NeuroPace With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
